A study of ARGX-110 as a monotherapy for the treatment of relapsed/refractory cutaneous T-cell lymphoma (CTCL)

Trial Profile

A study of ARGX-110 as a monotherapy for the treatment of relapsed/refractory cutaneous T-cell lymphoma (CTCL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs ARGX 110 (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Oct 2017 According to an argenx media release, interim data expected by the 2017 American Society of Hematology (ASH) Annual Meeting (December, 2017).
    • 02 May 2017 According to an argenx media release, the company expects topline data by the end of 2018.
    • 20 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top